Trial Profile
A Pilot Study of Stereotactic Radiosurgery Combined With Nivolumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Brain metastases; Cancer metastases; Malignant melanoma
- Focus Adverse reactions
- 29 Nov 2021 Status changed from recruiting to completed.
- 01 Feb 2021 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 01 Feb 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.